IL166706A0 - Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation - Google Patents

Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation

Info

Publication number
IL166706A0
IL166706A0 IL16670605A IL16670605A IL166706A0 IL 166706 A0 IL166706 A0 IL 166706A0 IL 16670605 A IL16670605 A IL 16670605A IL 16670605 A IL16670605 A IL 16670605A IL 166706 A0 IL166706 A0 IL 166706A0
Authority
IL
Israel
Prior art keywords
aggregation
compositions
treatment
methods
exhibiting protein
Prior art date
Application number
IL16670605A
Other languages
English (en)
Original Assignee
Univ Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Delaware filed Critical Univ Delaware
Publication of IL166706A0 publication Critical patent/IL166706A0/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
IL16670605A 2002-08-07 2005-02-06 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation IL166706A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40219802P 2002-08-07 2002-08-07
PCT/US2003/024868 WO2004014306A2 (en) 2002-08-07 2003-08-07 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation

Publications (1)

Publication Number Publication Date
IL166706A0 true IL166706A0 (en) 2006-01-15

Family

ID=31715805

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16670605A IL166706A0 (en) 2002-08-07 2005-02-06 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation

Country Status (10)

Country Link
EP (1) EP1575510A4 (ja)
JP (1) JP2006509726A (ja)
KR (1) KR20050053607A (ja)
CN (1) CN101123993A (ja)
AU (1) AU2003259073A1 (ja)
CA (1) CA2494908A1 (ja)
IL (1) IL166706A0 (ja)
NO (1) NO20051159L (ja)
NZ (1) NZ538145A (ja)
WO (1) WO2004014306A2 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007139120A1 (ja) * 2006-05-30 2007-12-06 Osaka University アミロイドβクリアランス促進剤
KR100982909B1 (ko) * 2009-07-08 2010-09-20 고려대학교 산학협력단 아탁신-1 유전자 또는 아탁신-1 단백질을 유효성분으로 포함하는 항암용 조성물 및 그를 이용한 항암제 스크리닝 방법
WO2011015572A1 (en) * 2009-08-03 2011-02-10 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases
US11492617B2 (en) 2017-08-08 2022-11-08 Ionis Pharmaceuticals, Inc Compositions and methods for modulation of protein aggregation
US20220411794A1 (en) 2019-10-23 2022-12-29 Universitaet Wien Rna oligonucleotides for preventing aggregation of proteins
WO2023205579A1 (en) * 2022-04-18 2023-10-26 The Regents Of The University Of California Compositions and methods for disrupting pathological aggregates

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3495297A (en) * 1996-07-08 1998-02-02 Pioneer Hi-Bred International, Inc. Transformation of zygote, egg or sperm cells and recovery of transformed plants from isolated embryo sacs
WO1999006545A2 (en) * 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
US7799535B1 (en) * 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
EP1135113B1 (en) * 1998-11-05 2008-10-01 Thomas Jefferson University Treatment of parkinson's disease with oligonucleotides
DE19925073C2 (de) * 1999-06-01 2001-07-19 Stefan Weiss Nucleinsäuremoleküle mit spezifischer Erkennung von nativem PrP·S··c·, Herstellung und Verwendung
US6420122B1 (en) * 1999-09-27 2002-07-16 Massachusetts Institute Of Technology Methods of screening for agents that inhibit aggregation of polypeptides
WO2002054083A2 (en) * 2001-01-03 2002-07-11 Ortho-Mcneil Pharmaceutical, Inc. Alpha synuclein aggregation assays
US7045290B2 (en) * 2001-02-15 2006-05-16 The University Of Chicago Yeast screens for treatment of human disease
CA2455424A1 (en) * 2001-08-07 2003-02-20 University Of Delaware Compositions and methods for the prevention and treatment of huntington's disease
CA2468145A1 (en) * 2001-11-21 2003-05-30 Japan Science And Technology Agency Transcriptional factors for the huntington's disease gene
US20030235823A1 (en) * 2002-06-24 2003-12-25 The University Of Alabama Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation

Also Published As

Publication number Publication date
KR20050053607A (ko) 2005-06-08
JP2006509726A (ja) 2006-03-23
EP1575510A2 (en) 2005-09-21
WO2004014306A2 (en) 2004-02-19
NZ538145A (en) 2008-05-30
EP1575510A4 (en) 2007-12-26
AU2003259073A1 (en) 2004-02-25
CA2494908A1 (en) 2004-02-19
NO20051159L (no) 2005-04-26
CN101123993A (zh) 2008-02-13
WO2004014306A3 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
EP1575480A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
EP1578367A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1572116A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
EP1576137A4 (en) COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
EP1578421A4 (en) PHARMACEUTICAL PREPARATIONS FOR THE TREATMENT OF DISEASES AND BREAST CONDITIONS
EP1560593A4 (en) NEW COMPOSITION AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
AU2003246102A8 (en) Method of examining allergic disease and drug for treating the same
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1572091A4 (en) COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING TUMORS
AU2003268531A8 (en) Materials and methods for treatment of allergic diseases
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1553912A4 (en) COMPOSITIONS AND METHODS FOR TUMOR DIAGNOSIS AND TREATMENT
AU2003216592A8 (en) Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
HK1162127A1 (en) Oil body associated protein compositions and methods as well as use thereof for reducing the risk of cardiovascular disease
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
IL166706A0 (en) Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
EP1578373A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
EP1562587A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OF THE IMMUNE SYSTEM